康宁杰瑞制药-B(09966.HK) 公布,JSKN033(HER2双特异性抗体偶联药物与PD-L1免疫检查点抑制剂的高浓度皮下注射复方制剂)的一项I/II期临床试验已获国家药品监督管理局药品审评中心新药临床试验申请批准。
I/II期临床试验旨在评估JSKN033在晚期转移性恶性肿瘤患者中的安全性、耐受性、药代动力学/药效学及抗肿瘤活性,并确定最大耐受剂量及/或推荐II期剂量。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-24 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.